427 related articles for article (PubMed ID: 33624334)
21. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.
Balducci C; Beeg M; Stravalaci M; Bastone A; Sclip A; Biasini E; Tapella L; Colombo L; Manzoni C; Borsello T; Chiesa R; Gobbi M; Salmona M; Forloni G
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2295-300. PubMed ID: 20133875
[TBL] [Abstract][Full Text] [Related]
22. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Um JW; Strittmatter SM
Prion; 2013; 7(1):37-41. PubMed ID: 22987042
[TBL] [Abstract][Full Text] [Related]
23. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
Laurén J; Gimbel DA; Nygaard HB; Gilbert JW; Strittmatter SM
Nature; 2009 Feb; 457(7233):1128-32. PubMed ID: 19242475
[TBL] [Abstract][Full Text] [Related]
24. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
25. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Yang F; Lim GP; Begum AN; Ubeda OJ; Simmons MR; Ambegaokar SS; Chen PP; Kayed R; Glabe CG; Frautschy SA; Cole GM
J Biol Chem; 2005 Feb; 280(7):5892-901. PubMed ID: 15590663
[TBL] [Abstract][Full Text] [Related]
26. Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures.
Bate C; Williams A
Neurobiol Dis; 2018 Mar; 111():48-58. PubMed ID: 29272738
[TBL] [Abstract][Full Text] [Related]
27. PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.
Mengel D; Hong W; Corbett GT; Liu W; DeSousa A; Solforosi L; Fang C; Frosch MP; Collinge J; Harris DA; Walsh DM
Brain Res; 2019 May; 1710():125-135. PubMed ID: 30593771
[TBL] [Abstract][Full Text] [Related]
28. Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.
Vergara C; Ordóñez-Gutiérrez L; Wandosell F; Ferrer I; del Río JA; Gavín R
Mol Neurobiol; 2015; 51(3):1206-20. PubMed ID: 24965601
[TBL] [Abstract][Full Text] [Related]
29. Binding between Prion Protein and Aβ Oligomers Contributes to the Pathogenesis of Alzheimer's Disease.
Kong C; Xie H; Gao Z; Shao M; Li H; Shi R; Cai L; Gao S; Sun T; Li C
Virol Sin; 2019 Oct; 34(5):475-488. PubMed ID: 31093882
[TBL] [Abstract][Full Text] [Related]
30. Brain amyloid-β oligomers in ageing and Alzheimer's disease.
Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH
Brain; 2013 May; 136(Pt 5):1383-98. PubMed ID: 23576130
[TBL] [Abstract][Full Text] [Related]
31. Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity.
Pagano K; Galante D; D'Arrigo C; Corsaro A; Nizzari M; Florio T; Molinari H; Tomaselli S; Ragona L
Mol Neurobiol; 2019 Mar; 56(3):1957-1971. PubMed ID: 29981054
[TBL] [Abstract][Full Text] [Related]
32. Memory impairment in transgenic Alzheimer mice requires cellular prion protein.
Gimbel DA; Nygaard HB; Coffey EE; Gunther EC; Laurén J; Gimbel ZA; Strittmatter SM
J Neurosci; 2010 May; 30(18):6367-74. PubMed ID: 20445063
[TBL] [Abstract][Full Text] [Related]
33. Amyloid-beta oligomers increase the localization of prion protein at the cell surface.
Caetano FA; Beraldo FH; Hajj GN; Guimaraes AL; Jürgensen S; Wasilewska-Sampaio AP; Hirata PH; Souza I; Machado CF; Wong DY; De Felice FG; Ferreira ST; Prado VF; Rylett RJ; Martins VR; Prado MA
J Neurochem; 2011 May; 117(3):538-53. PubMed ID: 21352228
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM
Nat Neurosci; 2012 Sep; 15(9):1227-35. PubMed ID: 22820466
[TBL] [Abstract][Full Text] [Related]
35. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues.
Chen S; Yadav SP; Surewicz WK
J Biol Chem; 2010 Aug; 285(34):26377-83. PubMed ID: 20576610
[TBL] [Abstract][Full Text] [Related]
36. Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
Purro SA; Farmer M; Noble E; Sarell CJ; Powell M; Yip D; Giggins L; Zakka L; Thomas DX; Farrow M; Nicoll AJ; Walsh D; Collinge J
PLoS One; 2023; 18(11):e0294465. PubMed ID: 37976283
[TBL] [Abstract][Full Text] [Related]
37. β-amyloid oligomers and prion protein: Fatal attraction?
Forloni G; Balducci C
Prion; 2011; 5(1):10-5. PubMed ID: 21150333
[TBL] [Abstract][Full Text] [Related]
38. Specific amyloid-β42 deposition in the brain of a Gerstmann-Sträussler-Scheinker disease patient with a P105L mutation on the prion protein gene.
Furukawa F; Sanjo N; Kobayashi A; Hamaguchi T; Yamada M; Kitamoto T; Mizusawa H; Yokota T
Prion; 2018; 12(5-6):315-319. PubMed ID: 30394185
[TBL] [Abstract][Full Text] [Related]
39. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
Brody DL; Jiang H; Wildburger N; Esparza TJ
Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
[TBL] [Abstract][Full Text] [Related]
40. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
Wirths O; Bethge T; Marcello A; Harmeier A; Jawhar S; Lucassen PJ; Multhaup G; Brody DL; Esparza T; Ingelsson M; Kalimo H; Lannfelt L; Bayer TA
J Neural Transm (Vienna); 2010 Jan; 117(1):85-96. PubMed ID: 19823761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
